J S Abramson1, T Feldman2, A R Kroll-Desrosiers3, L S Muffly4, E Winer5, C R Flowers6, F Lansigan7, C Nabhan4, L J Nastoupil6, R Nath3, A Goy2, J J Castillo8, D Jagadeesh3, B Woda3, S T Rosen9, S M Smith4, A M Evens10. 1. Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston. 2. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack. 3. Department of Hematology/Oncology, University of Massachusetts Medical School, Worcester. 4. Department of Hematology/Oncology, University of Chicago, Chicago. 5. Department of Hematology/Oncology, Rhode Island Hospital, Providence. 6. Department of Hematology/Oncology, Emory University School of Medicine, Atlanta. 7. Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon. 8. Department of Hematology/Oncology, Miriam Hospital, Providence. 9. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago. 10. Department of Hematology/Oncology, Tufts Medical Center, Boston, USA. Electronic address: aevens@tuftsmedicalcenter.org.
Abstract
BACKGROUND: Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear. PATIENTS AND METHODS: We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using univariate and multivariate analyses. RESULTS: PTCL subtypes included PTCL, not otherwise specified (PTCL-NOS) (31%), anaplastic large T-cell lymphoma (ALCL) (26%), angioimmunoblastic T-cell lymphoma (23%), NK/T-cell lymphoma (7%), acute T-cell leukemia/lymphoma (6%), and other (7%). Median age was 62 years (range 18-95 years), and 74% had stage III-IV disease. Twenty-three (7%) patients received only palliative care whereas 318 received chemotherapy: CHOP-like regimens (70%), hyperCVAD/MA (6%), or other (18%). Thirty-three patients (10%) underwent stem-cell transplantation (SCT) in first remission. The overall response rate was 73% (61% complete); 24% had primary refractory disease. With 39-month median follow-up, 3-year progression-free survival (PFS) and overall survival (OS) were 32% and 52%. PFS and OS for PTCL patients were significantly inferior to matched patients with DLBCL. On multivariate analysis, stage I-II disease was the only significant pretreatment prognostic factor [PFS: hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.34-0.85, P = 0.007; OS: HR 0.42, 95% CI 0.22-0.78, P = 0.006]. ALK positivity in ALCL was prognostic on univariate analysis, but lost significance on multivariate analysis. The most dominant prognostic factor was response to initial therapy (complete response versus other), including adjustment for stage and SCT [PFS: HR 0.19, 95% CI 0.14-0.28, P < 0.0001; OS: HR 0.26, 95% CI 0.17-0.40, P < 0.0001]. No overall survival difference was observed based on choice of upfront regimen or SCT in first remission. CONCLUSIONS: This analysis identifies early-stage disease and initial treatment response as dominant prognostic factors in PTCL. No clear benefit was observed for patients undergoing consolidative SCT. Novel therapeutic approaches for PTCL are critically needed.
BACKGROUND: Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear. PATIENTS AND METHODS: We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using univariate and multivariate analyses. RESULTS: PTCL subtypes included PTCL, not otherwise specified (PTCL-NOS) (31%), anaplastic large T-cell lymphoma (ALCL) (26%), angioimmunoblastic T-cell lymphoma (23%), NK/T-cell lymphoma (7%), acute T-cell leukemia/lymphoma (6%), and other (7%). Median age was 62 years (range 18-95 years), and 74% had stage III-IV disease. Twenty-three (7%) patients received only palliative care whereas 318 received chemotherapy: CHOP-like regimens (70%), hyperCVAD/MA (6%), or other (18%). Thirty-three patients (10%) underwent stem-cell transplantation (SCT) in first remission. The overall response rate was 73% (61% complete); 24% had primary refractory disease. With 39-month median follow-up, 3-year progression-free survival (PFS) and overall survival (OS) were 32% and 52%. PFS and OS for PTCL patients were significantly inferior to matched patients with DLBCL. On multivariate analysis, stage I-II disease was the only significant pretreatment prognostic factor [PFS: hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.34-0.85, P = 0.007; OS: HR 0.42, 95% CI 0.22-0.78, P = 0.006]. ALK positivity in ALCL was prognostic on univariate analysis, but lost significance on multivariate analysis. The most dominant prognostic factor was response to initial therapy (complete response versus other), including adjustment for stage and SCT [PFS: HR 0.19, 95% CI 0.14-0.28, P < 0.0001; OS: HR 0.26, 95% CI 0.17-0.40, P < 0.0001]. No overall survival difference was observed based on choice of upfront regimen or SCT in first remission. CONCLUSIONS: This analysis identifies early-stage disease and initial treatment response as dominant prognostic factors in PTCL. No clear benefit was observed for patients undergoing consolidative SCT. Novel therapeutic approaches for PTCL are critically needed.
Authors: J Rodríguez; M D Caballero; A Gutiérrez; J Marín; J J Lahuerta; A Sureda; E Carreras; A León; R Arranz; A Fernández de Sevilla; J Zuazu; J García-Laraña; J Rifon; R Varela; M Gandarillas; J SanMiguel; E Conde Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: Maricer P Escalón; Nina S Liu; Ying Yang; Mark Hess; Pamela L Walker; Terry L Smith; Nam H Dang Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: Maryska L G Janssen-Heijnen; Dick Johan van Spronsen; Valery E P P Lemmens; Saskia Houterman; Kees D G W Verheij; Jan Willem W Coebergh Journal: Br J Haematol Date: 2005-06 Impact factor: 6.998
Authors: Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger Journal: Blood Date: 2008-04-02 Impact factor: 22.113
Authors: S Feyler; H M Prince; R Pearce; K Towlson; I Nivison-Smith; S Schey; J Gibson; N Patton; K Bradstock; D I Marks; G Cook Journal: Bone Marrow Transplant Date: 2007-06-25 Impact factor: 5.483
Authors: Ranjana H Advani; Stephen M Ansell; Mary J Lechowicz; Anne W Beaven; Fausto Loberiza; Kenneth R Carson; Andrew M Evens; Francine Foss; Steven Horwitz; Barbara Pro; Lauren C Pinter-Brown; Sonali M Smith; Andrei R Shustov; Kerry J Savage; Julie M Vose Journal: Br J Haematol Date: 2015-12-02 Impact factor: 6.998
Authors: Joseph Roswarski; Mark Roschewski; Christopher Melani; Stefania Pittaluga; Andrea Lucas; Seth M Steinberg; Elaine S Jaffe; Thomas A Waldmann; Wyndham H Wilson Journal: Leuk Lymphoma Date: 2019-01-10
Authors: Steven I Park; Steven M Horwitz; Francine M Foss; Lauren C Pinter-Brown; Kenneth R Carson; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark Acosta; Ranjana H Advani; Tatyana Feldman; Mary Jo Lechowicz; Sonali M Smith; Frederick Lansigan; Anil Tulpule; Michael D Craig; John P Greer; Brad S Kahl; Joseph W Leach; Neil Morganstein; Carla Casulo; Andrei R Shustov Journal: Cancer Date: 2019-01-29 Impact factor: 6.860